TY - JOUR
T1 - Treated HIV infection and progression of carotid atherosclerosis in rural uganda
T2 - A prospective observational cohort study
AU - Siedner, Mark J.
AU - Bibangambah, Prossy
AU - Kim, June Ho
AU - Lankowski, Alexander
AU - Chang, Jonathan L.
AU - Yang, Isabelle T.
AU - Kwon, Douglas S.
AU - North, Crystal M.
AU - Triant, Virginia A.
AU - Longenecker, Christopher
AU - Ghoshhajra, Brian
AU - Peck, Robert N.
AU - Sentongo, Ruth N.
AU - Gilbert, Rebecca
AU - Kakuhikire, Bernard
AU - Boum, Yap
AU - Haberer, Jessica E.
AU - Martin, Jeffrey N.
AU - Tracy, Russell
AU - Hunt, Peter W.
AU - Bangsberg, David R.
AU - Tsai, Alexander C.
AU - Hemphill, Linda C.
AU - Okello, Samson
N1 - Funding Information:
We are extremely appreciative of the partnership, dedication, and patience of the Ugandan AIDS Rural Treatment Outcomes Study, Ugandan Non-communicable Diseases and Aging Cohort Study, and HopeNet study participants and field staff for their commitment to this work.This study was funded by the U.S. National Institutes of Health (R21 HL124712, P30 AI060354, R24 AG044325, P30 AG024409, P30 AI027763, R01 HL141053, D43 TW010543, R25TW009337, T32HL116275, R01MH113494, and R01MH125667), and the Massachusetts General Hospital Executive Committee on Research. Yang reports additional research support from the Geisel School of Medicine at Dartmouth. The content is solely the responsi-bility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2021 The Authors.
PY - 2021/6/15
Y1 - 2021/6/15
N2 - BACKGROUND: Although ≈70% of the world’s population of people living with HIV reside in sub-Saharan Africa, there are minimal prospective data on the contributions of HIV infection to atherosclerosis in the region. METHODS AND RESULTS: We conducted a prospective observational cohort study of people living with HIV on antiretroviral therapy >40 years of age in rural Uganda, along with population-based comparators not infected with HIV. We collected data on cardiovascular disease risk factors and carotid ultrasound measurements annually. We fitted linear mixed effects mod-els, adjusted for cardiovascular disease risk factors, to estimate the association between HIV serostatus and progression of carotid intima media thickness (cIMT). We enrolled 155 people living with HIV and 154 individuals not infected with HIV and collected cIMT images at 1045 visits during a median of 4 annual visits per participant (interquartile range 3–4, range 1–5). Age (median 50.9 years) and sex (49% female) were similar by HIV serostatus. At enrollment, there was no difference in mean cIMT by HIV serostatus (0.665 versus 0.680 mm, P=0.15). In multivariable models, increasing age, blood pressure, and non– high-density lipoprotein cholesterol were associated with greater cIMT (P<0.05), however change in cIMT per year was also no different by HIV serostatus (0.004 mm/year for HIV negative [95% CI, 0.001–0.007 mm], 0.006 mm/year for people living with HIV [95% CI, 0.003–0.008 mm], HIV×time interaction P=0.25). CONCLUSIONS: In rural Uganda, treated HIV infection was not associated with faster cIMT progression. These results do not support classification of treated HIV infection as a risk factor for subclinical atherosclerosis progression in rural sub-Saharan Africa. REGISTRATION: URL: https://www.ClinicalTrials.gov; Unique identifier: NCT02445079.
AB - BACKGROUND: Although ≈70% of the world’s population of people living with HIV reside in sub-Saharan Africa, there are minimal prospective data on the contributions of HIV infection to atherosclerosis in the region. METHODS AND RESULTS: We conducted a prospective observational cohort study of people living with HIV on antiretroviral therapy >40 years of age in rural Uganda, along with population-based comparators not infected with HIV. We collected data on cardiovascular disease risk factors and carotid ultrasound measurements annually. We fitted linear mixed effects mod-els, adjusted for cardiovascular disease risk factors, to estimate the association between HIV serostatus and progression of carotid intima media thickness (cIMT). We enrolled 155 people living with HIV and 154 individuals not infected with HIV and collected cIMT images at 1045 visits during a median of 4 annual visits per participant (interquartile range 3–4, range 1–5). Age (median 50.9 years) and sex (49% female) were similar by HIV serostatus. At enrollment, there was no difference in mean cIMT by HIV serostatus (0.665 versus 0.680 mm, P=0.15). In multivariable models, increasing age, blood pressure, and non– high-density lipoprotein cholesterol were associated with greater cIMT (P<0.05), however change in cIMT per year was also no different by HIV serostatus (0.004 mm/year for HIV negative [95% CI, 0.001–0.007 mm], 0.006 mm/year for people living with HIV [95% CI, 0.003–0.008 mm], HIV×time interaction P=0.25). CONCLUSIONS: In rural Uganda, treated HIV infection was not associated with faster cIMT progression. These results do not support classification of treated HIV infection as a risk factor for subclinical atherosclerosis progression in rural sub-Saharan Africa. REGISTRATION: URL: https://www.ClinicalTrials.gov; Unique identifier: NCT02445079.
KW - Atherosclerosis
KW - Cardiovascular disease risk
KW - Carotid intima media thickness
KW - HIV infection
KW - Uganda
KW - antiretroviral therapy
UR - http://www.scopus.com/inward/record.url?scp=85108304172&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108304172&partnerID=8YFLogxK
U2 - 10.1161/JAHA.120.019994
DO - 10.1161/JAHA.120.019994
M3 - Article
C2 - 34096320
AN - SCOPUS:85108304172
SN - 2047-9980
VL - 10
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 12
M1 - e019994
ER -